$961 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 148 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | ISHARES TRput | $99,496,000 | – | 8,000 | +100.0% | 10.36% | – | |
| New | SPDR S&P 500 ETF TRput | $72,251,000 | – | 3,500 | +100.0% | 7.52% | – | |
| New | SPDR SERIES TRUSTput | $33,063,000 | – | 1,500 | +100.0% | 3.44% | – | |
| ABBV | New | ABBVIE INC | $23,826,000 | – | 407,000 | +100.0% | 2.48% | – |
| MRK | New | MERCK & CO INC NEW | $21,555,000 | – | 375,000 | +100.0% | 2.24% | – |
| AMGN | New | AMGEN INC | $19,214,000 | – | 120,200 | +100.0% | 2.00% | – |
| ENDP | New | ENDO INTL PLC | $18,837,000 | – | 210,000 | +100.0% | 1.96% | – |
| MYL | New | MYLAN N V | $16,149,000 | – | 272,100 | +100.0% | 1.68% | – |
| New | ISHARES TRput | $10,303,000 | – | 300 | +100.0% | 1.07% | – | |
| New | SELECT SECTOR SPDR TRput | $9,425,000 | – | 1,300 | +100.0% | 0.98% | – | |
| CELG | New | CELGENE CORP | $8,070,000 | – | 70,000 | +100.0% | 0.84% | – |
| SGEN | New | SEATTLE GENETICS INC | $7,070,000 | – | 200,000 | +100.0% | 0.74% | – |
| AZN | New | ASTRAZENECA PLCsponsored adr | $5,929,000 | – | 86,637 | +100.0% | 0.62% | – |
| CHKP | New | CHECK POINT SOFTWARE TECH LTord | $5,896,000 | – | 71,927 | +100.0% | 0.61% | – |
| INSYQ | New | INSYS THERAPEUTICS INC NEW | $5,813,000 | – | 100,000 | +100.0% | 0.60% | – |
| BLCM | New | BELLICUM PHARMACEUTICALS INC | $5,693,000 | – | 249,567 | +100.0% | 0.59% | – |
| AAPL | New | APPLE INC | $5,317,000 | – | 42,733 | +100.0% | 0.55% | – |
| INSM | New | INSMED INC | $5,200,000 | – | 250,000 | +100.0% | 0.54% | – |
| IPXL | New | IMPAX LABORATORIES INC | $4,687,000 | – | 100,000 | +100.0% | 0.49% | – |
| KYTH | New | KYTHERA BIOPHARMACEUTICALS I | $4,514,000 | – | 90,000 | +100.0% | 0.47% | – |
| DEPO | New | DEPOMED INC | $4,482,000 | – | 200,000 | +100.0% | 0.47% | – |
| ALDR | New | ALDER BIOPHARMACEUTICALS INC | $4,329,000 | – | 150,000 | +100.0% | 0.45% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $4,333,000 | – | 25,000 | +100.0% | 0.45% | – |
| AOS | New | SMITH A O | $4,045,000 | – | 61,600 | +100.0% | 0.42% | – |
| ARIA | New | ARIAD PHARMACEUTICALS INC | $3,667,000 | – | 445,000 | +100.0% | 0.38% | – |
| New | PTC THERAPEUTICS INCcall | $3,651,000 | – | 600 | +100.0% | 0.38% | – | |
| FEZ | New | SPDR INDEX SHS FDSeuro stoxx 50 | $3,649,000 | – | 94,000 | +100.0% | 0.38% | – |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $3,582,000 | – | 150,000 | +100.0% | 0.37% | – |
| New | DYAX CORPput | $3,351,000 | – | 2,000 | +100.0% | 0.35% | – | |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $3,334,000 | – | 36,000 | +100.0% | 0.35% | – |
| EWG | New | ISHARESmsci germany etf | $3,223,000 | – | 108,000 | +100.0% | 0.34% | – |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $3,185,000 | – | 1,300,000 | +100.0% | 0.33% | – |
| GWPH | New | GW PHARMACEUTICALS PLCads | $3,190,000 | – | 35,000 | +100.0% | 0.33% | – |
| VFC | New | V F CORP | $3,176,000 | – | 42,170 | +100.0% | 0.33% | – |
| PRGO | New | PERRIGO CO PLC | $3,046,000 | – | 18,400 | +100.0% | 0.32% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $2,932,000 | – | 100,000 | +100.0% | 0.30% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $2,926,000 | – | 105,000 | +100.0% | 0.30% | – |
| EPZM | New | EPIZYME INC | $2,817,000 | – | 150,000 | +100.0% | 0.29% | – |
| New | MEDICINES COcall | $2,802,000 | – | 1,000 | +100.0% | 0.29% | – | |
| TTPH | New | TETRAPHASE PHARMACEUTICALS I | $2,748,000 | – | 75,000 | +100.0% | 0.29% | – |
| IMDZ | New | IMMUNE DESIGN CORP | $2,732,000 | – | 129,440 | +100.0% | 0.28% | – |
| RTRX | New | RETROPHIN INC | $2,669,000 | – | 111,392 | +100.0% | 0.28% | – |
| ATRA | New | ATARA BIOTHERAPEUTICS INC | $2,643,000 | – | 63,579 | +100.0% | 0.28% | – |
| PAY | New | VERIFONE SYS INC | $2,636,000 | – | 75,545 | +100.0% | 0.27% | – |
| OTIC | New | OTONOMY INC | $2,475,000 | – | 70,000 | +100.0% | 0.26% | – |
| AAVL | New | AVALANCHE BIOTECHNOLOGIES IN | $2,431,000 | – | 60,000 | +100.0% | 0.25% | – |
| TXMD | New | THERAPEUTICSMD INC | $2,208,000 | – | 365,000 | +100.0% | 0.23% | – |
| ITEK | New | INOTEK PHARMACEUTICALS CORP | $2,168,000 | – | 400,000 | +100.0% | 0.23% | – |
| SMMT | New | SUMMIT THERAPEUTICS PLCspons ads | $2,168,000 | – | 175,000 | +100.0% | 0.23% | – |
| ITB | New | ISHARESus home cons etf | $2,145,000 | – | 76,000 | +100.0% | 0.22% | – |
| PCLN | New | PRICELINE GRP INC | $2,119,000 | – | 1,820 | +100.0% | 0.22% | – |
| WAB | New | WABTEC CORP | $2,043,000 | – | 21,500 | +100.0% | 0.21% | – |
| SRCL | New | STERICYCLE INC | $2,036,000 | – | 14,500 | +100.0% | 0.21% | – |
| New | TRILLIUM THERAPEUTICS INC | $1,922,000 | – | 95,000 | +100.0% | 0.20% | – | |
| TTHI | New | TRANSITION THERAPEUTICS INC | $1,864,000 | – | 272,906 | +100.0% | 0.19% | – |
| ZSAN | New | ZOSANO PHARMA CORP | $1,866,000 | – | 184,619 | +100.0% | 0.19% | – |
| FOMX | New | FOAMIX PHARMACEUTICALS LTD | $1,850,000 | – | 200,000 | +100.0% | 0.19% | – |
| THRM | New | GENTHERM INC | $1,745,000 | – | 34,550 | +100.0% | 0.18% | – |
| CLLS | New | CELLECTIS S Asponsored ads | $1,729,000 | – | 50,000 | +100.0% | 0.18% | – |
| CNAT | New | CONATUS PHARMACEUTICALS INC | $1,566,000 | – | 220,000 | +100.0% | 0.16% | – |
| GALT | New | GALECTIN THERAPEUTICS INC | $1,508,000 | – | 450,000 | +100.0% | 0.16% | – |
| GNCA | New | GENOCEA BIOSCIENCES INC | $1,473,000 | – | 124,200 | +100.0% | 0.15% | – |
| ASMB | New | ASSEMBLY BIOSCIENCES INC | $1,324,000 | – | 100,000 | +100.0% | 0.14% | – |
| EXEL | New | EXELIXIS INC | $1,285,000 | – | 500,000 | +100.0% | 0.13% | – |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $1,215,000 | – | 70,000 | +100.0% | 0.13% | – |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $1,194,000 | – | 115,000 | +100.0% | 0.12% | – |
| STML | New | STEMLINE THERAPEUTICS INC | $1,171,000 | – | 80,957 | +100.0% | 0.12% | – |
| SGNT | New | SAGENT PHARMACEUTICALS INC | $1,163,000 | – | 50,000 | +100.0% | 0.12% | – |
| HRTX | New | HERON THERAPEUTICS INC | $1,163,000 | – | 79,900 | +100.0% | 0.12% | – |
| IMMU | New | IMMUNOMEDICS INC | $1,149,000 | – | 300,000 | +100.0% | 0.12% | – |
| EARS | New | AURIS MED HLDG AG | $997,000 | – | 186,300 | +100.0% | 0.10% | – |
| OHRP | New | OHR PHARMACEUTICAL INC | $476,000 | – | 187,500 | +100.0% | 0.05% | – |
| SPNS | New | SAPIENS INTL CORP N V | $463,000 | – | 56,420 | +100.0% | 0.05% | – |
| BLRX | New | BIOLINERX LTDsponsored adr | $408,000 | – | 193,284 | +100.0% | 0.04% | – |
| SPPI | New | SPECTRUM PHARMACEUTICALS INC | $304,000 | – | 50,000 | +100.0% | 0.03% | – |
| LMNS | New | LUMENIS LTD | $0 | – | 245 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.